By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Drugs > Isoproterenol (monograph) > Isoproterenol Dosage
Drugs
https://themeditary.com/dosage-information/isoproterenol-dosage-9389.html

Isoproterenol Dosage

Drug Detail:Isoproterenol (monograph) (Medically reviewed)

Drug Class:

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Adams-Stokes Syndrome

IV Bolus:

  • Initial dose: 0.02 to 0.06 mg IV bolus
  • Subsequent dose range: 0.01 to 0.2 mg

IV Infusion:
  • Initial dose: 5 mcg/min via IV infusion

IM:
  • Initial dose: 0.2 mg IM
  • Subsequent dose range: 0.02 to 1 mg IM

Subcutaneous:
  • Initial dose: 0.2 mg subcutaneously
  • Subsequent dose range: 0.15 to 0.2 mg subcutaneously

Intracardiac:
  • Initial dose: 0.02 mg via intracardiac route

Comments:
  • Subcutaneous, intracardiac, and IM doses should be administered using undiluted solution.
  • Bolus IV doses should be administered after diluting 1 mL (0.2 mg) in 9 mL of sodium chloride or 5% dextrose injection.
  • IV infusion doses should be administered after diluting 10 mL (2 mg) in 500 mL of 5% dextrose injection.
  • Subsequent doses and method of administration depend on ventricular rate and rapidity with which the cardiac pacemaker can take over when the drug is gradually withdrawn.

Uses: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy; for serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation); and for use in cardiac arrest until electric shock or pacemaker therapy is available

Usual Adult Dose for AV Heart Block

IV Bolus:

  • Initial dose: 0.02 to 0.06 mg IV bolus
  • Subsequent dose range: 0.01 to 0.2 mg

IV Infusion:
  • Initial dose: 5 mcg/min via IV infusion

IM:
  • Initial dose: 0.2 mg IM
  • Subsequent dose range: 0.02 to 1 mg IM

Subcutaneous:
  • Initial dose: 0.2 mg subcutaneously
  • Subsequent dose range: 0.15 to 0.2 mg subcutaneously

Intracardiac:
  • Initial dose: 0.02 mg via intracardiac route

Comments:
  • Subcutaneous, intracardiac, and IM doses should be administered using undiluted solution.
  • Bolus IV doses should be administered after diluting 1 mL (0.2 mg) in 9 mL of sodium chloride or 5% dextrose injection.
  • IV infusion doses should be administered after diluting 10 mL (2 mg) in 500 mL of 5% dextrose injection.
  • Subsequent doses and method of administration depend on ventricular rate and rapidity with which the cardiac pacemaker can take over when the drug is gradually withdrawn.

Uses: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy; for serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation); and for use in cardiac arrest until electric shock or pacemaker therapy is available

Usual Adult Dose for Cardiac Arrest

IV Bolus:

  • Initial dose: 0.02 to 0.06 mg IV bolus
  • Subsequent dose range: 0.01 to 0.2 mg

IV Infusion:
  • Initial dose: 5 mcg/min via IV infusion

IM:
  • Initial dose: 0.2 mg IM
  • Subsequent dose range: 0.02 to 1 mg IM

Subcutaneous:
  • Initial dose: 0.2 mg subcutaneously
  • Subsequent dose range: 0.15 to 0.2 mg subcutaneously

Intracardiac:
  • Initial dose: 0.02 mg via intracardiac route

Comments:
  • Subcutaneous, intracardiac, and IM doses should be administered using undiluted solution.
  • Bolus IV doses should be administered after diluting 1 mL (0.2 mg) in 9 mL of sodium chloride or 5% dextrose injection.
  • IV infusion doses should be administered after diluting 10 mL (2 mg) in 500 mL of 5% dextrose injection.
  • Subsequent doses and method of administration depend on ventricular rate and rapidity with which the cardiac pacemaker can take over when the drug is gradually withdrawn.

Uses: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy; for serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation); and for use in cardiac arrest until electric shock or pacemaker therapy is available

Usual Adult Dose for Shock

Initial dose: 0.5 to 5 mcg/min via IV infusion

Comments:

  • Dilute 5 mL (1 mg) in 500 mL of 5% dextrose injection prior to administration.
  • Consider decreasing or temporarily stopping the infusion if the heart rate exceeds 100 beats per minute.
  • Concentrations up to 10 times greater have been used when limitation of volume is essential.
  • Rates over 30 mcg per minute have been used in advanced stages of shock.
  • The rate of infusion should be adjusted based on heart rate, central venous pressure, systemic blood pressure, and urine flow.

Uses: As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock

Usual Adult Dose for Bronchospasm During Anesthesia

Initial dose: 0.01 to 0.02 mg IV bolus; may be repeated when necessary

Comments:

  • Dilute 1 mL (0.2 mg) in 9 mL of sodium chloride or 5% dextrose injection.

Use: For the treatment of bronchospasm during anesthesia

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Elderly: Initiate at the low end of the dosing range due to increased likelihood for decreased hepatic, renal, or cardiac function or presence of concomitant diseases or other drug therapy.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Begin therapy with the lowest recommended dose and increase rate of administration gradually if needed while carefully monitoring patient.
  • Intracardiac injection should only be used in dire emergencies; if time is not of the utmost importance, initial therapy by IM or subcutaneous injection is preferred.

Storage requirements:
  • Protect from light.
  • Keep in opaque container until use.

Reconstitution/preparation techniques:
  • Do not use if injection is pinkish or darker than slightly yellow or contains precipitate.

Monitoring:
  • Cardiovascular: Routinely monitor systemic blood pressure, heart rate, and the electrocardiograph.
  • Genitourinary: Routinely monitor urine flow.
  • Monitor response to therapy by frequent determination of central venous pressure and blood gases.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by